PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include targeting and compensation services, and pharmaceutical audit suite; brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. The company conducts clinical trials in the areas of pharmaceutical development, including oncology, central nervous system, inflammation, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone919-786-8200
Debt
Current Ratio0.89
Quick Ratio0.89
Price-To-Earnings
Sales & Book Value
Annual Sales$2.26 billion
Price / Sales2.85
Price / Cash Flow20.95
Price / Book6.71
Profitability
Net Income$86.92 million
Net Margins2.37%
Return on Assets7.48%
Miscellaneous
Employees15,800
OptionableOptionable
PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions
What is PRA Health Sciences' stock symbol?
PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."
How were PRA Health Sciences' earnings last quarter?
PRA Health Sciences Inc (NASDAQ:PRAH) issued its earnings results on Wednesday, October, 31st. The medical research company reported $1.13 EPS for the quarter, topping the consensus estimate of $1.07 by $0.06. The medical research company earned $717.60 million during the quarter, compared to analysts' expectations of $729.63 million. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. PRA Health Sciences's quarterly revenue was up 23.3% compared to the same quarter last year. During the same period last year, the business earned $0.88 earnings per share. View PRA Health Sciences' Earnings History.
When is PRA Health Sciences' next earnings date?
What guidance has PRA Health Sciences issued on next quarter's earnings?
PRA Health Sciences issued an update on its FY18 earnings guidance on Wednesday, October, 31st. The company provided EPS guidance of $4.22-4.27 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.19. The company issued revenue guidance of $2.87-2.92 billion, compared to the consensus revenue estimate of $2.91 billion.PRA Health Sciences also updated its FY 2018 guidance to $4.22-4.27 EPS.
What price target have analysts set for PRAH?
8 Wall Street analysts have issued 12-month target prices for PRA Health Sciences' stock. Their forecasts range from $100.00 to $120.00. On average, they anticipate PRA Health Sciences' stock price to reach $113.50 in the next year. This suggests a possible upside of 14.5% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.
What is the consensus analysts' recommendation for PRA Health Sciences?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PRA Health Sciences.
Has PRA Health Sciences been receiving favorable news coverage?
Media headlines about PRAH stock have been trending positive on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PRA Health Sciences earned a news sentiment score of 2.6 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an impact on the company's share price in the next few days.
Who are some of PRA Health Sciences' key competitors?
Some companies that are related to PRA Health Sciences include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL) and Senomyx (SNMX).
Who are PRA Health Sciences' key executives?
PRA Health Sciences' management team includes the folowing people:
- Mr. Colin Shannon, Chairman, CEO & Pres (Age 60)
- Mr. Michael J. Bonello, Exec. VP & CFO
- Christine Rogers, Director of PR & Corp. Communications
- Mr. Patrick R. Spine, VP of HR
- Mr. Pedro Vinals, VP of Operations & GP
When did PRA Health Sciences IPO?
(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.
Who are PRA Health Sciences' major shareholders?
PRA Health Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Retirement Systems of Alabama (0.12%), Scout Investments Inc. (0.10%), Navellier & Associates Inc (0.08%), Gateway Investment Advisers LLC (0.03%), Louisiana State Employees Retirement System (0.02%) and KAMES CAPITAL plc (0.02%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.
Which major investors are selling PRA Health Sciences stock?
PRAH stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., KAMES CAPITAL plc, Fox Run Management L.L.C., Oakbrook Investments LLC, Louisiana State Employees Retirement System and CENTRAL TRUST Co. View Insider Buying and Selling for PRA Health Sciences.
Which major investors are buying PRA Health Sciences stock?
PRAH stock was purchased by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, Highland Capital Management LLC, Meeder Asset Management Inc., Retirement Systems of Alabama, Navellier & Associates Inc and State of Alaska Department of Revenue. View Insider Buying and Selling for PRA Health Sciences.
How do I buy shares of PRA Health Sciences?
Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PRA Health Sciences' stock price today?
One share of PRAH stock can currently be purchased for approximately $99.15.
How big of a company is PRA Health Sciences?
PRA Health Sciences has a market capitalization of $6.39 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.
What is PRA Health Sciences' official website?
How can I contact PRA Health Sciences?
PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]
MarketBeat Community Rating for PRA Health Sciences (NASDAQ PRAH)
MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote "Outperform" if you believe PRAH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAH will underperform the S&P 500 over the long term. You may vote once every thirty days.
